82 citations,
February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
66 citations,
April 2017 in “International Journal of Andrology” Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
44 citations,
January 2012 in “Food and chemical toxicology” Ursolic acid can shrink the prostate and lower a hormone linked to prostate growth in rats.
[object Object] 
30 citations,
January 2008 in “The Aging Male” The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.
24 citations,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
23 citations,
May 1984 in “Journal of the American Geriatrics Society” Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.
21 citations,
January 1998 in “Urologia internationalis” All treatments helped with prostate symptoms, but the combination of dibenyline and finasteride worked best without extra side effects.
20 citations,
October 2018 in “Clinical Drug Investigation” Dutasteride does not impair mental function in elderly men with enlarged prostate.
[object Object] 
20 citations,
August 2018 in “The World Journal of Men's Health” Finasteride may increase erectile dysfunction risk in patients with benign prostatic hyperplasia.
20 citations,
June 2017 in “Hormone Molecular Biology and Clinical Investigation” Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.